Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Letermovir

FDA-approved product (tablet, oral), marketed as Prevymis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Letermovir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cytomegalovirus infection
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antivirals
FDA pharmacologic class
Cytomegalovirus DNA Terminase Complex Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX18

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Letermovir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Letermovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)

    NCT03930615 · start 2019-06-21

    Registered record
    Registry ID
    NCT03930615
    Conditions
    Cytomegalovirus Infection
    Interventions
    Letermovir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-06-21
    Completion
    2022-03-16
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infection
    InterventionLetermovir; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

    NCT03728426 · start 2019-01-11

    Registered record
    Registry ID
    NCT03728426
    Conditions
    Cytomegalovirus Infections
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-11
    Completion
    2022-03-28
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections
    InterventionLetermovir
    PhasePhase 2
    Registry statusCompleted

  • Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

    NCT03443869 · start 2018-05-03

    Registered record
    Registry ID
    NCT03443869
    Conditions
    CMV Disease
    Interventions
    Letermovir; Valganciclovir; Acyclovir (ACV); Placebo to ACV; Placebo to LET; Placebo to VGCV
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-03
    Completion
    2022-04-05
    Enrolment
    601

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Disease
    InterventionLetermovir; Valganciclovir; Acyclovir (ACV); Placebo to ACV +2 more
    PhasePhase 3
    Registry statusCompleted

  • Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

    NCT02137772 · start 2014-06-06

    Registered record
    Registry ID
    NCT02137772
    Conditions
    Prevention of CMV Infection or Disease
    Interventions
    Letermovir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-06
    Completion
    2016-11-21
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrevention of CMV Infection or Disease
    InterventionLetermovir; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

    NCT01063829 · start 2010-03

    Registered record
    Registry ID
    NCT01063829
    Conditions
    HCMV Reactivation or HCMV End-Organ Disease
    Interventions
    60 mg AIC246; 120 mg AIC246; 240 mg AIC246; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-12
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCMV Reactivation or HCMV End-Organ Disease
    Intervention60 mg AIC246; 120 mg AIC246; 240 mg AIC246; Placebo
    PhasePhase 2
    Registry statusCompleted